search
Back to results

Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery

Primary Purpose

Cataract, Preoperative Sedation

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Dextrometropine and 0.9% sodium chloride solution
Sponsored by
Guangzhou First People's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cataract focused on measuring Cataract, Preoperative sedation, Dextromethoridine, Patient satisfaction

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Cataract patients over 65 years scheduled for elective phacoemulsification and intraocular lens implantation in Department of Ophthalmology, Guangzhou First People's Hospital will be recruited in this study. Recruited patients shall own normal intelligence and understanding capability and their best corrected visual acuity more than 0.1 in either eye. Exclusion Criteria: 1) a known allergy or hypersensitivity to dextrometropine or other anesthetics; 2) a previous history of heart disease; 3) a heart rate (HR) <45 beats per minute (bpm); 4) a second- or third-degree atrioventricular block; 5) patients on antihypertensive drugs, such as α-methyldopa, clonidine, or other α2-adrenergic agonists; 6) asthma; 7) sleep apnea syndrome; 8) organ dysfunction; 9) patients with mental illness; and 10) the long-term use of sedatives and analgesics. -

Sites / Locations

  • Guangzhou First People's HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

dextrometropine group

placebo group

Arm Description

Approximately 45 - 60 minutes before cataract surgery, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1).

Approximately 45 - 60 minutes before cataract surgery, patients in the placebo group were given 0.9% sodium chloride solution (1.0μg.kg-1).

Outcomes

Primary Outcome Measures

Overall patients satisfaction with preoperative sedation
Patient satisfaction was assessed using a 3-point satisfaction score on a scale (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable). The minimum value is 1 and maximum is 3. Higher scores mean a worse outcome.
Anxiety of perioperative patients
Anxiety of perioperative patients was assessed using a 4-point anxiety score (1 = combative, 2 = anxious, 3 = calm, and 4 = amiable). The minimum value is 1 and maximum is 4. Higher scores mean a better outcome.

Secondary Outcome Measures

Effects of preoperative sedation on patients' vital signs and operation time
Blood pressure, heart rate, blood oxygen saturation, operation time, operative complications and adverse drug reactions

Full Information

First Posted
January 16, 2023
Last Updated
February 4, 2023
Sponsor
Guangzhou First People's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05698758
Brief Title
Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery
Official Title
A Randomized Controlled Trial of Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 10, 2023 (Actual)
Primary Completion Date
March 31, 2023 (Anticipated)
Study Completion Date
March 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Guangzhou First People's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators designed this study to examine whether the intranasal dexmedetomidine, as a preoperative drug, could improve the satisfaction of adult patients undergoing phacoemulsification cataract surgery.
Detailed Description
This is a prospective, double-blind, randomized controlled study. Patients over 65 years old were selected for phacoemulsification combined with intraocular lens implantation under topical anesthesia. Participants were randomly divided into two groups: dextrometropine group and placebo group, and were masked until the end of this study. Approximately 45 - 60 minutes before surface anesthesia, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1), patients in the placebo group were given the same amount of saline. The primary end point of this study is the patient satisfaction. Patient satisfaction was assessed using a 3-point satisfaction score on a scale. Anxiety of perioperative patients was assessed using a 4-point anxiety score on a scale. Secondary endpoints include blood pressure, heart rate, blood oxygen saturation, operation time, operative complications and adverse drug reactions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract, Preoperative Sedation
Keywords
Cataract, Preoperative sedation, Dextromethoridine, Patient satisfaction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
dextrometropine group
Arm Type
Experimental
Arm Description
Approximately 45 - 60 minutes before cataract surgery, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1).
Arm Title
placebo group
Arm Type
Placebo Comparator
Arm Description
Approximately 45 - 60 minutes before cataract surgery, patients in the placebo group were given 0.9% sodium chloride solution (1.0μg.kg-1).
Intervention Type
Drug
Intervention Name(s)
Dextrometropine and 0.9% sodium chloride solution
Other Intervention Name(s)
Dexmedetomidine Hydrochloride
Intervention Description
Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
Primary Outcome Measure Information:
Title
Overall patients satisfaction with preoperative sedation
Description
Patient satisfaction was assessed using a 3-point satisfaction score on a scale (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable). The minimum value is 1 and maximum is 3. Higher scores mean a worse outcome.
Time Frame
Operation day
Title
Anxiety of perioperative patients
Description
Anxiety of perioperative patients was assessed using a 4-point anxiety score (1 = combative, 2 = anxious, 3 = calm, and 4 = amiable). The minimum value is 1 and maximum is 4. Higher scores mean a better outcome.
Time Frame
Operation day
Secondary Outcome Measure Information:
Title
Effects of preoperative sedation on patients' vital signs and operation time
Description
Blood pressure, heart rate, blood oxygen saturation, operation time, operative complications and adverse drug reactions
Time Frame
Perioperative period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cataract patients over 65 years scheduled for elective phacoemulsification and intraocular lens implantation in Department of Ophthalmology, Guangzhou First People's Hospital will be recruited in this study. Recruited patients shall own normal intelligence and understanding capability and their best corrected visual acuity more than 0.1 in either eye. Exclusion Criteria: 1) a known allergy or hypersensitivity to dextrometropine or other anesthetics; 2) a previous history of heart disease; 3) a heart rate (HR) <45 beats per minute (bpm); 4) a second- or third-degree atrioventricular block; 5) patients on antihypertensive drugs, such as α-methyldopa, clonidine, or other α2-adrenergic agonists; 6) asthma; 7) sleep apnea syndrome; 8) organ dysfunction; 9) patients with mental illness; and 10) the long-term use of sedatives and analgesics. -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yuehong Zhang, PhD
Phone
86-02081048225
Email
carmenzhangyh@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Zhimeng Zhang, PhD
Phone
86-02081048225
Email
598527019@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yuehong Zhang, PhD
Organizational Affiliation
Guangzhou First People's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Guangzhou First People's Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510180
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuehong Zhang, MD, PhD
Phone
+862081048225
Email
carmenzhangyh@163.com
First Name & Middle Initial & Last Name & Degree
Yuehong Zhang, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery

We'll reach out to this number within 24 hrs